|
1
|
Wang L, Lu B, He M, Wang Y, Wang Z and Du
L: Prostate cancer incidence and mortality: Global status and
temporal trends in 89 countries from 2000 to 2019. Front Public
Heal. 10(811044)2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bratt O, Auvinen A, Arnsrud Godtman R,
Hellström M, Hugosson J, Lilja H, Wallström J and Roobol MJ:
Screening for prostate cancer: Evidence, ongoing trials, policies
and knowledge gaps. BMJ Oncol. 2(e000039)2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chakrabortty A, Patton DJ, Smith BF and
Agarwal P: miRNAs: Potential as biomarkers and therapeutic targets
for cancer. Genes (Basel). 14(1375)2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Calin GA, Liu CG, Sevignani C, Ferracin M,
Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, et al:
MicroRNA profiling reveals distinct signatures in B cell chronic
lymphocytic leukemias. Proc Natl Acad Sci USA. 101:11755–11760.
2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Porkka KP, Pfeiffer MJ, Waltering KK,
Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression
profiling in prostate cancer. Cancer Res. 67:6130–6135.
2007.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Rhim J, Baek W, Seo Y and Kim JH: From
molecular mechanisms to therapeutics: Understanding MicroRNA-21 in
cancer. Cells. 11(2791)2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Liu LZ, Li C, Chen Q, Jing Y, Carpenter R,
Jiang Y, Kung HF, Lai L and Jiang BH: MiR-21 induced angiogenesis
through AKT and ERK activation and HIF-1α expression. PLoS One.
6(e19139)2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Vanacore D, Boccellino M, Rossetti S,
Cavaliere C, D'Aniello C, Di Franco R, Romano FJ, Montanari M, La
Mantia E, Piscitelli R, et al: Micrornas in prostate cancer: An
overview. Oncotarget. 8:50240–50251. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Galardi S, Mercatelli N, Giorda E,
Massalini S, Frajese GV, Ciafrè SA and Farace MG: miR-221 and
miR-222 expression affects the proliferation potential of human
prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem.
282:23716–23724. 2007.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Amir S, Ma AH, Shi XB, Xue L, Kung HJ and
Devere White RW: Oncomir miR-125b suppresses p14(ARF) to modulate
p53-dependent and p53-independent apoptosis in prostate cancer.
PLoS One. 8(e61064)2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kalfert D, Ludvikova M, Pesta M, Ludvik J,
Dostalova L and Kholová I: Multifunctional roles of miR-34a in
cancer: A review with the emphasis on head and neck squamous cell
carcinoma and thyroid cancer with clinical implications.
Diagnostics (Basel). 10(563)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Yamamura S, Saini S, Majid S, Hirata H,
Ueno K, Deng G and Dahiya R: MicroRNA-34a modulates c-Myc
transcriptional complexes to suppress malignancy in human prostate
cancer cells. PLoS One. 7(e29722)2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cavallari I, Ciccarese F, Sharova E, Urso
L, Raimondi V, Silic-Benussi M, D'Agostino DM and Ciminale V: The
miR-200 family of microRNAs: Fine tuners of epithelial-mesenchymal
transition and circulating cancer biomarkers. Cancers (Basel).
13(5874)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ahmad J, Hasnain SE, Siddiqui MA, Ahamed
M, Musarrat J and Al-Khedhairy AA: MicroRNA in carcinogenesis &
cancer diagnostics: A new paradigm. Indian J Med Res. 137:680–694.
2013.PubMed/NCBI
|
|
16
|
Menon A, Abd-Aziz N, Khalid K, Poh CL and
Naidu R: miRNA: A promising therapeutic target in cancer. Int J Mol
Sci. 23(11502)2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Folini M, Gandellini P, Longoni N, Profumo
V, Callari M, Pennati M, Colecchia M, Supino R, Veneroni S,
Salvioni R, et al: miR-21: An oncomir on strike in prostate cancer.
Mol Cancer. 9(12)2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kneitz B, Krebs M, Kalogirou C, Schubert
M, Joniau S, van Poppel H, Lerut E, Kneitz S, Scholz CJ, Ströbel P,
et al: Survival in patients with high-risk prostate cancer is
predicted by miR-221, which regulates proliferation, apoptosis, and
invasion of prostate cancer cells by inhibiting IRF2 and SOCS3.
Cancer Res. 74:2591–2603. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Huang W, Kang XL, Cen S, Wang Y and Chen
X: High-level expression of microRNA-21 in peripheral blood
mononuclear cells is a diagnostic and prognostic marker in prostate
cancer. Genet Test Mol Biomarkers. 19:469–475. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wang W, Li J, Zhu W, Gao C, Jiang R, Li W,
Hu Q and Zhang B: MicroRNA-21 and the clinical outcomes of various
carcinomas: A systematic review and meta-analysis. BMC Cancer.
14(819)2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Gunawan RR, Astuti I and Danarto HR:
miRNA-21 as high potential prostate cancer biomarker in prostate
cancer patients in Indonesia. Asian Pac J Cancer Prev.
24:1095–1099. 2023.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Yaman Agaoglu F, Kovancilar M, Dizdar Y,
Darendeliler E, Holdenrieder S, Dalay N and Gezer U: Investigation
of miR-21, miR-141, and miR-221 in blood circulation of patients
with prostate cancer. Tumor Biol. 32:583–588. 2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kachris S, Papadaki C, Rounis K, Tsitoura
E, Kokkinaki C, Nikolaou C, Sourvinos G and Mavroudis D:
Circulating miRNAs as potential biomarkers in prostate cancer
patients undergoing radiotherapy. Cancer Manag Res. 13:8257–8271.
2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sun T, Yang M, Chen S, Balk S, Pomerantz
M, Hsieh CL, Brown M, Lee GM and Kantoff PW: The altered expression
of MiR-221/-222 and MiR-23b/-27b is associated with the development
of human castration resistant prostate cancer. Prostate.
72:1093–1103. 2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Song C, Chen H, Wang T, Zhang W, Ru G and
Lang J: Expression profile analysis of microRNAs in prostate cancer
by next-generation sequencing. Prostate. 75:500–516.
2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Coarfa C, Fiskus W, Eedunuri VK,
Rajapakshe K, Foley C, Chew SA, Shah SS, Geng C, Shou J, Mohamed
JS, et al: Comprehensive proteomic profiling identifies the
androgen receptor axis and other signaling pathways as targets of
microRNAs suppressed in metastatic prostate cancer. Oncogene.
35:2345–2356. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Spahn M, Kneitz S, Scholz CJ, Stenger N,
Rüdiger T, Ströbel P, Riedmiller H and Kneitz B: Expression of
microRNA-221 is progressively reduced in aggressive prostate cancer
and metastasis and predicts clinical recurrence. Int J Cancer.
127:394–403. 2010.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Guan C, Zhang L, Wang S, Long L, Zhou H,
Qian S, Ma M, Bai F, Meng QH and Lyu J: Upregulation of MicroRNA-21
promotes tumorigenesis of prostate cancer cells by targeting KLF5.
Cancer Biol Ther. 20:1149–1161. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ibrahim NH, Abdellateif MS, Kassem SH, Abd
El Salam MA and El Gammal MM: Diagnostic significance of miR-21,
miR-141, miR-18a and miR-221 as novel biomarkers in prostate cancer
among Egyptian patients. Andrologia. 51(e13384)2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Stafford MYC, Willoughby CE, Walsh CP and
McKenna DJ: Prognostic value of miR-21 for prostate cancer: A
systematic review and meta-analysis. Biosci Rep.
42(BSR20211972)2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sun T, Wang Q, Balk S, Brown M, Lee GS and
Kantoff P: The role of microRNA-221 and microRNA-222 in
androgen-independent prostate cancer cell lines. Cancer Res.
69:3356–3363. 2009.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kang SG, Ha YR, Kim SJ, Kang SH, Park HS,
Lee JG, Cheon J and Kim CH: Do microRNA 96, 145 and 221 expressions
really aid in the prognosis of prostate carcinoma? Asian J Androl.
14:752–757. 2012.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Porzycki P, Ciszkowicz E, Semik M and
Tyrka M: Combination of three miRNA (miR-141, miR-21, and miR-375)
as potential diagnostic tool for prostate cancer recognition. Int
Urol Nephrol. 50:1619–1626. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhou H and Zhu X: MicroRNA-21 and
microRNA-30c as diagnostic biomarkers for prostate cancer: A
meta-analysis. Cancer Manag Res. 11:2039–2050. 2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Seputra KP, Purnomo BB, Susianti H, Kalim
H and Purnomo AF: miRNA-21 as reliable serum diagnostic biomarker
candidate for metastatic progressive prostate cancer: Meta-analysis
approach. Med Arch. 75:347–350. 2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Hekımler Öztürk K, Mutlu İçduygu F, Özgöz
A and Özorak A: miR-221, miR-650 and miR-4534 as diagnostic markers
in prostate cancer and their relationship with lymphatic invasion.
Turk J Biochem. 47:435–443. 2022.
|
|
37
|
Li S, Yang X, Yang J, Zhen J and Zhang D:
Serum microRNA-21 as a potential diagnostic biomarker for breast
cancer: A systematic review and meta-analysis. Clin Exp Med.
16:29–35. 2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Rihane FE, Erguibi D, Abumsimir B,
Charoute H, Chehab F and Ennaji MM: Expression of microRNAs in
gastric cancerous tissues and their association with Helicobacter
pylori and Epstein-Barr virus infections. World Acad Sci J.
4(1)2022.
|
|
39
|
Lamsisi M, Li G, Benhessou M, El Mzibri M,
Bouziyane A, Wakrime L, Laraqui A, Ennaji Y, Abumsimir B, El
Karroumi M, et al: Long noncoding RNA HOTAIR as a biomarker for the
detection of cervical cancer and cervical intraepithelial
neoplasia. Indian J Gynecol Oncol. 19(69)2021.
|
|
40
|
Shah MY and Calin GA: MicroRNAs miR-221
and miR-222: A new level of regulation in aggressive breast cancer.
Genome Med. 3(56)2011.PubMed/NCBI View
Article : Google Scholar
|
|
41
|
Li F: Expression of miR-221 and miR-489 in
breast cancer patients and their relationship with prognosis. Oncol
Lett. 19:1523–1529. 2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Liang L, Zheng X, Hu M, Cui Y, Zhong Q,
Wang S and Huang F: MiRNA-221/222 in thyroid cancer: A
meta-analysis. Clin Chim Acta. 484:284–292. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Franceschi C and Campisi J: Chronic
inflammation (inflammaging) and its potential contribution to
age-associated diseases. J Gerontol A Biol Sci Med Sci. 69 (Suppl
1):S4–S9. 2014.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899.
2010.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Beskow LM and Dean E: Informed consent for
biorepositories: Assessing prospective participants' understanding
and opinions. Cancer Epidemiol Biomarkers Prev. 17:1440–1451.
2008.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444.
2008.PubMed/NCBI View Article : Google Scholar
|
